TiGenix is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell (eASC) platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialized product. Its corporate headquarters are in

Leuven Leuven (, ) or Louvain (, , ; german: link=no, Löwen ) is the capital and largest city of the province of Flemish Brabant in the Flemish Region of Belgium. It is located about east of Brussels. The municipality itself comprises the historic ...

, Belgium, and it has operations in Madrid, Spain. TiGenix was founded in 2000 by Prof. Dr. Frank P. Luyten and Gil Beyen as a

spin-off Spin-off may refer to: *Spin-off (media), a media work derived from an existing work *Corporate spin-off, a type of corporate action that forms a new company or entity * Government spin-off, civilian goods which are the result of military or gove ...

from the

Katholieke Universiteit Leuven KU Leuven (or Katholieke Universiteit Leuven) is a Catholic research university in the city of Leuven, Belgium. It conducts teaching, research, and services in computer science, engineering, natural sciences, theology, humanities, medicine, l ...

and the

Ghent University Ghent University ( nl, Universiteit Gent, abbreviated as UGent) is a public research university located in Ghent, Belgium. Established before the state of Belgium itself, the university was founded by the Dutch King William I in 1817, when the ...

. TiGenix's therapeutic approach is to focus on the use of living cells rather than conventional drugs for the treatment of inflammatory and autoimmune diseases, through its eASC-based platform, and heart disease, through its CSC-based platform. TiGenix's pipeline of stem cell programs is based on validated platforms of allogeneic stem cells.

History

TiGenix has completed and received positive data in, a single pivotal Phase III trial in Europe of its most advanced product candidate Cx601, a potential first-in-class injectable allogeneic stem cell therapy indicated for the treatment of complex perianal fistulas in patients with

Crohn's disease Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract. Symptoms often include abdominal pain, diarrhea (which may be bloody if inflammation is severe), fever, abdominal distension ...

. On 28 July 2016 ''

The Lancet ''The Lancet'' is a weekly peer-reviewed general medical journal and one of the oldest of its kind. It is also the world's highest-impact academic journal. It was founded in England in 1823. The journal publishes original research articles, ...

'' published the results of their phase 3 ADMIRE-CD Trial.

Acquisition by Takeda

In early January 2018,

Takeda Pharmaceutical Company The is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 followin ...

announced it would acquire TiGenix for up to €520 million ($632 million).

References

External links

TiGenix website'Tigenix has been a rollercoaster', De Tijd, 14 May 2014
*
'Cx601 could be launched in 2017', L'Echo, 3 July 2014
* *{{youTube, id=LEBtZ7rvnvo, title=TiGenix at Alliance for Regenerative Medicine meeting, March 2015 Pharmaceutical companies established in 2000 Pharmaceutical companies disestablished in 2018 University spin-offs Biotechnology companies of Belgium 2000 establishments in Belgium Companies based in Leuven 2018 mergers and acquisitions